




PHARMACEUTICAL 2018

Assertio Therapeutics Inc
Rank 100 of 342





PHARMACEUTICAL 2018

Assertio Therapeutics Inc Rank 100 of 342

The relative strengths and weaknesses of Assertio Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Assertio Therapeutics Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 179% points. The greatest weakness of Assertio Therapeutics Inc is the variable Assets, Current, reducing the Economic Capital Ratio by 44% points.

The company's Economic Capital Ratio, given in the ranking table, is 170%, being 125% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	230,851
Cost of Goods Sold	0
Intangible Assets	793,873
Liabilities, Current	310,580
Liabilities, Non-Current	0
Other Assets	869
Other Compr. Net Income	14
Other Expenses	212,061
Other Liabilities	0
Other Net Income	-61,745
Other Revenues	380,724
Property and Equipment	13,024
Research and Development	13,718
Selling, General and Administrative Expense	195,696

Output Variable	Value in 1000 USD
Assets	1,038,617
Liabilities	310,580
Expenses	421,475
Revenues	380,724
Stockholders Equity	728,037
Net Income	-102,496
Comprehensive Net Income	-102,489
Economic Capital Ratio	170%